nodes	percent_of_prediction	percent_of_DWPC	metapath
Riluzole—ABCG2—Carboplatin—bone cancer	0.193	0.335	CbGbCtD
Riluzole—ABCG2—Cisplatin—bone cancer	0.165	0.287	CbGbCtD
Riluzole—ABCG2—Doxorubicin—bone cancer	0.11	0.192	CbGbCtD
Riluzole—ABCG2—Methotrexate—bone cancer	0.107	0.186	CbGbCtD
Riluzole—ABCG2—HIF-2-alpha transcription factor network—CITED2—bone cancer	0.00476	0.0895	CbGpPWpGaD
Riluzole—SCN5A—Cardiac Progenitor Differentiation—T—bone cancer	0.00464	0.0873	CbGpPWpGaD
Riluzole—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00392	0.0737	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.0028	0.0526	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—FEV—bone cancer	0.0023	0.0433	CbGpPWpGaD
Riluzole—CYP1A1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00202	0.0379	CbGpPWpGaD
Riluzole—ABCG2—Irinotecan Pathway—CYP3A4—bone cancer	0.00191	0.036	CbGpPWpGaD
Riluzole—CYP1A1—Benzo(a)pyrene metabolism—CYP3A4—bone cancer	0.00184	0.0347	CbGpPWpGaD
Riluzole—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00144	0.027	CbGpPWpGaD
Riluzole—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00129	0.0242	CbGpPWpGaD
Riluzole—CYP1A1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00116	0.0219	CbGpPWpGaD
Riluzole—ABCG2—Fluoropyrimidine Activity—DHFR—bone cancer	0.00114	0.0214	CbGpPWpGaD
Riluzole—CYP1A1—Estrogen metabolism—CYP3A4—bone cancer	0.00106	0.0199	CbGpPWpGaD
Riluzole—CYP1A1—Xenobiotics—CYP3A4—bone cancer	0.000973	0.0183	CbGpPWpGaD
Riluzole—CYP1A1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000936	0.0176	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—CYP4V2—bone cancer	0.000868	0.0163	CbGpPWpGaD
Riluzole—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000742	0.014	CbGpPWpGaD
Riluzole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000695	0.0131	CbGpPWpGaD
Riluzole—SLC7A11—NRF2 pathway—TGFBR2—bone cancer	0.000692	0.013	CbGpPWpGaD
Riluzole—SLC7A11—NRF2 pathway—GSTP1—bone cancer	0.000692	0.013	CbGpPWpGaD
Riluzole—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000675	0.0127	CbGpPWpGaD
Riluzole—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000647	0.0122	CbGpPWpGaD
Riluzole—SCN5A—Cardiac Progenitor Differentiation—KIT—bone cancer	0.00063	0.0118	CbGpPWpGaD
Riluzole—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000621	0.0117	CbGpPWpGaD
Riluzole—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000597	0.0112	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000553	0.0104	CbGpPWpGaD
Riluzole—CYP1A1—Estrogen Receptor Pathway—JUN—bone cancer	0.000549	0.0103	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000544	0.0102	CbGpPWpGaD
Riluzole—CYP1A1—Tryptophan metabolism—CYP3A4—bone cancer	0.0005	0.0094	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00047	0.00884	CbGpPWpGaD
Riluzole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.00041	0.00771	CbGpPWpGaD
Riluzole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000406	0.00764	CbGpPWpGaD
Riluzole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000404	0.0076	CbGpPWpGaD
Riluzole—CYP1A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000399	0.0075	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—SPARC—bone cancer	0.000361	0.00679	CbGpPWpGaD
Riluzole—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.00035	0.00658	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—GNA11—bone cancer	0.00033	0.00621	CbGpPWpGaD
Riluzole—CYP1A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000328	0.00616	CbGpPWpGaD
Riluzole—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000319	0.006	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—IL3—bone cancer	0.000299	0.00563	CbGpPWpGaD
Riluzole—Sinusitis—Epirubicin—bone cancer	0.000296	0.000795	CcSEcCtD
Riluzole—Agranulocytosis—Epirubicin—bone cancer	0.000295	0.000791	CcSEcCtD
Riluzole—Pneumonia—Doxorubicin—bone cancer	0.000294	0.000788	CcSEcCtD
Riluzole—Infestation—Doxorubicin—bone cancer	0.000292	0.000784	CcSEcCtD
Riluzole—Infestation NOS—Doxorubicin—bone cancer	0.000292	0.000784	CcSEcCtD
Riluzole—Hypersensitivity—Cisplatin—bone cancer	0.000289	0.000775	CcSEcCtD
Riluzole—Bradycardia—Epirubicin—bone cancer	0.000289	0.000774	CcSEcCtD
Riluzole—Erythema multiforme—Methotrexate—bone cancer	0.000286	0.000768	CcSEcCtD
Riluzole—Neuropathy peripheral—Doxorubicin—bone cancer	0.000286	0.000768	CcSEcCtD
Riluzole—Haemoglobin—Epirubicin—bone cancer	0.000285	0.000764	CcSEcCtD
Riluzole—Jaundice—Doxorubicin—bone cancer	0.000285	0.000764	CcSEcCtD
Riluzole—Stomatitis—Doxorubicin—bone cancer	0.000285	0.000764	CcSEcCtD
Riluzole—Rhinitis—Epirubicin—bone cancer	0.000284	0.000762	CcSEcCtD
Riluzole—Urinary tract infection—Doxorubicin—bone cancer	0.000284	0.000762	CcSEcCtD
Riluzole—Hepatitis—Epirubicin—bone cancer	0.000283	0.000761	CcSEcCtD
Riluzole—Haemorrhage—Epirubicin—bone cancer	0.000283	0.000761	CcSEcCtD
Riluzole—Eye disorder—Methotrexate—bone cancer	0.000283	0.000759	CcSEcCtD
Riluzole—Hypoaesthesia—Epirubicin—bone cancer	0.000282	0.000757	CcSEcCtD
Riluzole—Asthenia—Cisplatin—bone cancer	0.000281	0.000755	CcSEcCtD
Riluzole—Pharyngitis—Epirubicin—bone cancer	0.000281	0.000755	CcSEcCtD
Riluzole—Cardiac disorder—Methotrexate—bone cancer	0.000281	0.000754	CcSEcCtD
Riluzole—Sweating—Doxorubicin—bone cancer	0.00028	0.000751	CcSEcCtD
Riluzole—Urinary tract disorder—Epirubicin—bone cancer	0.00028	0.000751	CcSEcCtD
Riluzole—Oedema peripheral—Epirubicin—bone cancer	0.000279	0.000749	CcSEcCtD
Riluzole—Haematuria—Doxorubicin—bone cancer	0.000279	0.000747	CcSEcCtD
Riluzole—Connective tissue disorder—Epirubicin—bone cancer	0.000279	0.000747	CcSEcCtD
Riluzole—Urethral disorder—Epirubicin—bone cancer	0.000278	0.000746	CcSEcCtD
Riluzole—Hepatobiliary disease—Doxorubicin—bone cancer	0.000276	0.000741	CcSEcCtD
Riluzole—Epistaxis—Doxorubicin—bone cancer	0.000276	0.000739	CcSEcCtD
Riluzole—Angiopathy—Methotrexate—bone cancer	0.000275	0.000737	CcSEcCtD
Riluzole—Sinusitis—Doxorubicin—bone cancer	0.000274	0.000735	CcSEcCtD
Riluzole—Immune system disorder—Methotrexate—bone cancer	0.000274	0.000734	CcSEcCtD
Riluzole—Mediastinal disorder—Methotrexate—bone cancer	0.000273	0.000732	CcSEcCtD
Riluzole—Agranulocytosis—Doxorubicin—bone cancer	0.000273	0.000732	CcSEcCtD
Riluzole—Chills—Methotrexate—bone cancer	0.000272	0.000729	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000269	0.00507	CbGpPWpGaD
Riluzole—Diarrhoea—Cisplatin—bone cancer	0.000268	0.00072	CcSEcCtD
Riluzole—Erythema multiforme—Epirubicin—bone cancer	0.000268	0.000719	CcSEcCtD
Riluzole—Alopecia—Methotrexate—bone cancer	0.000268	0.000718	CcSEcCtD
Riluzole—Bradycardia—Doxorubicin—bone cancer	0.000267	0.000716	CcSEcCtD
Riluzole—Mental disorder—Methotrexate—bone cancer	0.000265	0.000712	CcSEcCtD
Riluzole—Eye disorder—Epirubicin—bone cancer	0.000265	0.000711	CcSEcCtD
Riluzole—Malnutrition—Methotrexate—bone cancer	0.000264	0.000707	CcSEcCtD
Riluzole—Haemoglobin—Doxorubicin—bone cancer	0.000264	0.000707	CcSEcCtD
Riluzole—Cardiac disorder—Epirubicin—bone cancer	0.000263	0.000706	CcSEcCtD
Riluzole—Rhinitis—Doxorubicin—bone cancer	0.000263	0.000705	CcSEcCtD
Riluzole—Hepatitis—Doxorubicin—bone cancer	0.000262	0.000704	CcSEcCtD
Riluzole—Haemorrhage—Doxorubicin—bone cancer	0.000262	0.000704	CcSEcCtD
Riluzole—Hypoaesthesia—Doxorubicin—bone cancer	0.000261	0.0007	CcSEcCtD
Riluzole—Pharyngitis—Doxorubicin—bone cancer	0.00026	0.000698	CcSEcCtD
Riluzole—Urinary tract disorder—Doxorubicin—bone cancer	0.000259	0.000695	CcSEcCtD
Riluzole—Oedema peripheral—Doxorubicin—bone cancer	0.000258	0.000693	CcSEcCtD
Riluzole—Dysgeusia—Methotrexate—bone cancer	0.000258	0.000693	CcSEcCtD
Riluzole—Connective tissue disorder—Doxorubicin—bone cancer	0.000258	0.000692	CcSEcCtD
Riluzole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000258	0.00485	CbGpPWpGaD
Riluzole—Angiopathy—Epirubicin—bone cancer	0.000257	0.00069	CcSEcCtD
Riluzole—Urethral disorder—Doxorubicin—bone cancer	0.000257	0.00069	CcSEcCtD
Riluzole—Immune system disorder—Epirubicin—bone cancer	0.000256	0.000687	CcSEcCtD
Riluzole—Mediastinal disorder—Epirubicin—bone cancer	0.000255	0.000685	CcSEcCtD
Riluzole—Back pain—Methotrexate—bone cancer	0.000255	0.000684	CcSEcCtD
Riluzole—Chills—Epirubicin—bone cancer	0.000254	0.000682	CcSEcCtD
Riluzole—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000254	0.00478	CbGpPWpGaD
Riluzole—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	0.000254	0.00478	CbGpPWpGaD
Riluzole—Arrhythmia—Epirubicin—bone cancer	0.000253	0.000679	CcSEcCtD
Riluzole—Alopecia—Epirubicin—bone cancer	0.00025	0.000672	CcSEcCtD
Riluzole—Vomiting—Cisplatin—bone cancer	0.000249	0.000669	CcSEcCtD
Riluzole—Mental disorder—Epirubicin—bone cancer	0.000248	0.000666	CcSEcCtD
Riluzole—Erythema multiforme—Doxorubicin—bone cancer	0.000248	0.000665	CcSEcCtD
Riluzole—Rash—Cisplatin—bone cancer	0.000247	0.000663	CcSEcCtD
Riluzole—Dermatitis—Cisplatin—bone cancer	0.000247	0.000663	CcSEcCtD
Riluzole—Malnutrition—Epirubicin—bone cancer	0.000247	0.000662	CcSEcCtD
Riluzole—Eye disorder—Doxorubicin—bone cancer	0.000245	0.000658	CcSEcCtD
Riluzole—Ill-defined disorder—Methotrexate—bone cancer	0.000245	0.000656	CcSEcCtD
Riluzole—Anaemia—Methotrexate—bone cancer	0.000244	0.000654	CcSEcCtD
Riluzole—Cardiac disorder—Doxorubicin—bone cancer	0.000243	0.000653	CcSEcCtD
Riluzole—Flatulence—Epirubicin—bone cancer	0.000243	0.000652	CcSEcCtD
Riluzole—Tension—Epirubicin—bone cancer	0.000242	0.00065	CcSEcCtD
Riluzole—Dysgeusia—Epirubicin—bone cancer	0.000242	0.000648	CcSEcCtD
Riluzole—Nervousness—Epirubicin—bone cancer	0.00024	0.000643	CcSEcCtD
Riluzole—Back pain—Epirubicin—bone cancer	0.000239	0.00064	CcSEcCtD
Riluzole—Angiopathy—Doxorubicin—bone cancer	0.000238	0.000638	CcSEcCtD
Riluzole—Malaise—Methotrexate—bone cancer	0.000238	0.000638	CcSEcCtD
Riluzole—Muscle spasms—Epirubicin—bone cancer	0.000237	0.000637	CcSEcCtD
Riluzole—Immune system disorder—Doxorubicin—bone cancer	0.000237	0.000636	CcSEcCtD
Riluzole—Vertigo—Methotrexate—bone cancer	0.000237	0.000636	CcSEcCtD
Riluzole—Mediastinal disorder—Doxorubicin—bone cancer	0.000236	0.000634	CcSEcCtD
Riluzole—Leukopenia—Methotrexate—bone cancer	0.000236	0.000633	CcSEcCtD
Riluzole—Chills—Doxorubicin—bone cancer	0.000235	0.000631	CcSEcCtD
Riluzole—Arrhythmia—Doxorubicin—bone cancer	0.000234	0.000629	CcSEcCtD
Riluzole—Nausea—Cisplatin—bone cancer	0.000233	0.000625	CcSEcCtD
Riluzole—Alopecia—Doxorubicin—bone cancer	0.000232	0.000622	CcSEcCtD
Riluzole—Cough—Methotrexate—bone cancer	0.00023	0.000617	CcSEcCtD
Riluzole—Mental disorder—Doxorubicin—bone cancer	0.00023	0.000617	CcSEcCtD
Riluzole—CYP1A1—Tryptophan metabolism—MDM2—bone cancer	0.00023	0.00432	CbGpPWpGaD
Riluzole—Ill-defined disorder—Epirubicin—bone cancer	0.000229	0.000614	CcSEcCtD
Riluzole—Convulsion—Methotrexate—bone cancer	0.000228	0.000613	CcSEcCtD
Riluzole—Malnutrition—Doxorubicin—bone cancer	0.000228	0.000613	CcSEcCtD
Riluzole—Anaemia—Epirubicin—bone cancer	0.000228	0.000612	CcSEcCtD
Riluzole—Agitation—Epirubicin—bone cancer	0.000227	0.000608	CcSEcCtD
Riluzole—Flatulence—Doxorubicin—bone cancer	0.000225	0.000604	CcSEcCtD
Riluzole—Myalgia—Methotrexate—bone cancer	0.000224	0.000602	CcSEcCtD
Riluzole—Arthralgia—Methotrexate—bone cancer	0.000224	0.000602	CcSEcCtD
Riluzole—Chest pain—Methotrexate—bone cancer	0.000224	0.000602	CcSEcCtD
Riluzole—Tension—Doxorubicin—bone cancer	0.000224	0.000601	CcSEcCtD
Riluzole—Dysgeusia—Doxorubicin—bone cancer	0.000224	0.0006	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000223	0.000598	CcSEcCtD
Riluzole—Malaise—Epirubicin—bone cancer	0.000223	0.000597	CcSEcCtD
Riluzole—Discomfort—Methotrexate—bone cancer	0.000222	0.000595	CcSEcCtD
Riluzole—Nervousness—Doxorubicin—bone cancer	0.000222	0.000595	CcSEcCtD
Riluzole—Vertigo—Epirubicin—bone cancer	0.000222	0.000595	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000221	0.00417	CbGpPWpGaD
Riluzole—Syncope—Epirubicin—bone cancer	0.000221	0.000594	CcSEcCtD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000221	0.00416	CbGpPWpGaD
Riluzole—Leukopenia—Epirubicin—bone cancer	0.000221	0.000593	CcSEcCtD
Riluzole—Back pain—Doxorubicin—bone cancer	0.000221	0.000593	CcSEcCtD
Riluzole—Muscle spasms—Doxorubicin—bone cancer	0.000219	0.000589	CcSEcCtD
Riluzole—Palpitations—Epirubicin—bone cancer	0.000218	0.000585	CcSEcCtD
Riluzole—Confusional state—Methotrexate—bone cancer	0.000217	0.000582	CcSEcCtD
Riluzole—Loss of consciousness—Epirubicin—bone cancer	0.000217	0.000582	CcSEcCtD
Riluzole—Cough—Epirubicin—bone cancer	0.000215	0.000578	CcSEcCtD
Riluzole—Anaphylactic shock—Methotrexate—bone cancer	0.000215	0.000577	CcSEcCtD
Riluzole—Convulsion—Epirubicin—bone cancer	0.000214	0.000574	CcSEcCtD
Riluzole—Infection—Methotrexate—bone cancer	0.000214	0.000574	CcSEcCtD
Riluzole—Hypertension—Epirubicin—bone cancer	0.000213	0.000572	CcSEcCtD
Riluzole—Ill-defined disorder—Doxorubicin—bone cancer	0.000212	0.000568	CcSEcCtD
Riluzole—Nervous system disorder—Methotrexate—bone cancer	0.000211	0.000566	CcSEcCtD
Riluzole—Anaemia—Doxorubicin—bone cancer	0.000211	0.000566	CcSEcCtD
Riluzole—Thrombocytopenia—Methotrexate—bone cancer	0.000211	0.000565	CcSEcCtD
Riluzole—SCN5A—L1CAM interactions—EGFR—bone cancer	0.000211	0.00396	CbGpPWpGaD
Riluzole—Myalgia—Epirubicin—bone cancer	0.00021	0.000564	CcSEcCtD
Riluzole—Arthralgia—Epirubicin—bone cancer	0.00021	0.000564	CcSEcCtD
Riluzole—Chest pain—Epirubicin—bone cancer	0.00021	0.000564	CcSEcCtD
Riluzole—Agitation—Doxorubicin—bone cancer	0.00021	0.000563	CcSEcCtD
Riluzole—Anxiety—Epirubicin—bone cancer	0.000209	0.000562	CcSEcCtD
Riluzole—Skin disorder—Methotrexate—bone cancer	0.000209	0.000561	CcSEcCtD
Riluzole—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000209	0.00393	CbGpPWpGaD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000209	0.00056	CcSEcCtD
Riluzole—Hyperhidrosis—Methotrexate—bone cancer	0.000208	0.000558	CcSEcCtD
Riluzole—Discomfort—Epirubicin—bone cancer	0.000208	0.000557	CcSEcCtD
Riluzole—CYP1A1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000207	0.0039	CbGpPWpGaD
Riluzole—Malaise—Doxorubicin—bone cancer	0.000206	0.000552	CcSEcCtD
Riluzole—Dry mouth—Epirubicin—bone cancer	0.000205	0.000551	CcSEcCtD
Riluzole—Vertigo—Doxorubicin—bone cancer	0.000205	0.00055	CcSEcCtD
Riluzole—Anorexia—Methotrexate—bone cancer	0.000205	0.00055	CcSEcCtD
Riluzole—Syncope—Doxorubicin—bone cancer	0.000205	0.000549	CcSEcCtD
Riluzole—Leukopenia—Doxorubicin—bone cancer	0.000204	0.000548	CcSEcCtD
Riluzole—Confusional state—Epirubicin—bone cancer	0.000203	0.000545	CcSEcCtD
Riluzole—Palpitations—Doxorubicin—bone cancer	0.000202	0.000541	CcSEcCtD
Riluzole—Anaphylactic shock—Epirubicin—bone cancer	0.000201	0.00054	CcSEcCtD
Riluzole—Oedema—Epirubicin—bone cancer	0.000201	0.00054	CcSEcCtD
Riluzole—Hypotension—Methotrexate—bone cancer	0.000201	0.00054	CcSEcCtD
Riluzole—Loss of consciousness—Doxorubicin—bone cancer	0.000201	0.000538	CcSEcCtD
Riluzole—Infection—Epirubicin—bone cancer	0.0002	0.000537	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.0002	0.00376	CbGpPWpGaD
Riluzole—Cough—Doxorubicin—bone cancer	0.000199	0.000535	CcSEcCtD
Riluzole—Shock—Epirubicin—bone cancer	0.000198	0.000532	CcSEcCtD
Riluzole—Convulsion—Doxorubicin—bone cancer	0.000198	0.000531	CcSEcCtD
Riluzole—Nervous system disorder—Epirubicin—bone cancer	0.000197	0.00053	CcSEcCtD
Riluzole—Thrombocytopenia—Epirubicin—bone cancer	0.000197	0.000529	CcSEcCtD
Riluzole—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000197	0.00371	CbGpPWpGaD
Riluzole—Hypertension—Doxorubicin—bone cancer	0.000197	0.000529	CcSEcCtD
Riluzole—Tachycardia—Epirubicin—bone cancer	0.000197	0.000527	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—PLAU—bone cancer	0.000196	0.0037	CbGpPWpGaD
Riluzole—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000196	0.000526	CcSEcCtD
Riluzole—Skin disorder—Epirubicin—bone cancer	0.000196	0.000525	CcSEcCtD
Riluzole—Hyperhidrosis—Epirubicin—bone cancer	0.000195	0.000522	CcSEcCtD
Riluzole—Insomnia—Methotrexate—bone cancer	0.000195	0.000522	CcSEcCtD
Riluzole—Arthralgia—Doxorubicin—bone cancer	0.000194	0.000522	CcSEcCtD
Riluzole—Myalgia—Doxorubicin—bone cancer	0.000194	0.000522	CcSEcCtD
Riluzole—Chest pain—Doxorubicin—bone cancer	0.000194	0.000522	CcSEcCtD
Riluzole—Anxiety—Doxorubicin—bone cancer	0.000194	0.00052	CcSEcCtD
Riluzole—Paraesthesia—Methotrexate—bone cancer	0.000193	0.000518	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000193	0.000518	CcSEcCtD
Riluzole—Discomfort—Doxorubicin—bone cancer	0.000192	0.000515	CcSEcCtD
Riluzole—Anorexia—Epirubicin—bone cancer	0.000192	0.000515	CcSEcCtD
Riluzole—Dyspnoea—Methotrexate—bone cancer	0.000192	0.000515	CcSEcCtD
Riluzole—Somnolence—Methotrexate—bone cancer	0.000191	0.000513	CcSEcCtD
Riluzole—Dry mouth—Doxorubicin—bone cancer	0.00019	0.00051	CcSEcCtD
Riluzole—Dyspepsia—Methotrexate—bone cancer	0.000189	0.000508	CcSEcCtD
Riluzole—Hypotension—Epirubicin—bone cancer	0.000188	0.000505	CcSEcCtD
Riluzole—Confusional state—Doxorubicin—bone cancer	0.000188	0.000504	CcSEcCtD
Riluzole—Decreased appetite—Methotrexate—bone cancer	0.000187	0.000502	CcSEcCtD
Riluzole—Oedema—Doxorubicin—bone cancer	0.000186	0.0005	CcSEcCtD
Riluzole—Anaphylactic shock—Doxorubicin—bone cancer	0.000186	0.0005	CcSEcCtD
Riluzole—Gastrointestinal disorder—Methotrexate—bone cancer	0.000186	0.000498	CcSEcCtD
Riluzole—Fatigue—Methotrexate—bone cancer	0.000186	0.000498	CcSEcCtD
Riluzole—Infection—Doxorubicin—bone cancer	0.000185	0.000497	CcSEcCtD
Riluzole—Pain—Methotrexate—bone cancer	0.000184	0.000494	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000183	0.000492	CcSEcCtD
Riluzole—Shock—Doxorubicin—bone cancer	0.000183	0.000492	CcSEcCtD
Riluzole—Nervous system disorder—Doxorubicin—bone cancer	0.000183	0.00049	CcSEcCtD
Riluzole—Thrombocytopenia—Doxorubicin—bone cancer	0.000182	0.000489	CcSEcCtD
Riluzole—Insomnia—Epirubicin—bone cancer	0.000182	0.000489	CcSEcCtD
Riluzole—Tachycardia—Doxorubicin—bone cancer	0.000182	0.000488	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—JUN—bone cancer	0.000182	0.00342	CbGpPWpGaD
Riluzole—Skin disorder—Doxorubicin—bone cancer	0.000181	0.000486	CcSEcCtD
Riluzole—Paraesthesia—Epirubicin—bone cancer	0.000181	0.000485	CcSEcCtD
Riluzole—Hyperhidrosis—Doxorubicin—bone cancer	0.00018	0.000483	CcSEcCtD
Riluzole—Dyspnoea—Epirubicin—bone cancer	0.00018	0.000482	CcSEcCtD
Riluzole—Somnolence—Epirubicin—bone cancer	0.000179	0.00048	CcSEcCtD
Riluzole—Anorexia—Doxorubicin—bone cancer	0.000178	0.000477	CcSEcCtD
Riluzole—Feeling abnormal—Methotrexate—bone cancer	0.000177	0.000476	CcSEcCtD
Riluzole—Dyspepsia—Epirubicin—bone cancer	0.000177	0.000476	CcSEcCtD
Riluzole—Gastrointestinal pain—Methotrexate—bone cancer	0.000176	0.000472	CcSEcCtD
Riluzole—Decreased appetite—Epirubicin—bone cancer	0.000175	0.00047	CcSEcCtD
Riluzole—Hypotension—Doxorubicin—bone cancer	0.000174	0.000467	CcSEcCtD
Riluzole—CYP1A1—Biological oxidations—CYP3A4—bone cancer	0.000174	0.00327	CbGpPWpGaD
Riluzole—Gastrointestinal disorder—Epirubicin—bone cancer	0.000174	0.000466	CcSEcCtD
Riluzole—Fatigue—Epirubicin—bone cancer	0.000174	0.000466	CcSEcCtD
Riluzole—Pain—Epirubicin—bone cancer	0.000172	0.000462	CcSEcCtD
Riluzole—Constipation—Epirubicin—bone cancer	0.000172	0.000462	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000172	0.00323	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000172	0.00323	CbGpPWpGaD
Riluzole—Urticaria—Methotrexate—bone cancer	0.000171	0.000459	CcSEcCtD
Riluzole—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00017	0.0032	CbGpPWpGaD
Riluzole—Body temperature increased—Methotrexate—bone cancer	0.00017	0.000456	CcSEcCtD
Riluzole—Abdominal pain—Methotrexate—bone cancer	0.00017	0.000456	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00017	0.000455	CcSEcCtD
Riluzole—Insomnia—Doxorubicin—bone cancer	0.000169	0.000452	CcSEcCtD
Riluzole—Paraesthesia—Doxorubicin—bone cancer	0.000167	0.000449	CcSEcCtD
Riluzole—Dyspnoea—Doxorubicin—bone cancer	0.000166	0.000446	CcSEcCtD
Riluzole—Feeling abnormal—Epirubicin—bone cancer	0.000166	0.000445	CcSEcCtD
Riluzole—Somnolence—Doxorubicin—bone cancer	0.000166	0.000444	CcSEcCtD
Riluzole—Gastrointestinal pain—Epirubicin—bone cancer	0.000165	0.000442	CcSEcCtD
Riluzole—Dyspepsia—Doxorubicin—bone cancer	0.000164	0.00044	CcSEcCtD
Riluzole—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000162	0.00305	CbGpPWpGaD
Riluzole—Decreased appetite—Doxorubicin—bone cancer	0.000162	0.000435	CcSEcCtD
Riluzole—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000161	0.000432	CcSEcCtD
Riluzole—Fatigue—Doxorubicin—bone cancer	0.000161	0.000431	CcSEcCtD
Riluzole—Urticaria—Epirubicin—bone cancer	0.00016	0.000429	CcSEcCtD
Riluzole—Pain—Doxorubicin—bone cancer	0.000159	0.000428	CcSEcCtD
Riluzole—Constipation—Doxorubicin—bone cancer	0.000159	0.000428	CcSEcCtD
Riluzole—Body temperature increased—Epirubicin—bone cancer	0.000159	0.000427	CcSEcCtD
Riluzole—Abdominal pain—Epirubicin—bone cancer	0.000159	0.000427	CcSEcCtD
Riluzole—Hypersensitivity—Methotrexate—bone cancer	0.000159	0.000425	CcSEcCtD
Riluzole—SCN5A—Axon guidance—MET—bone cancer	0.000157	0.00296	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000157	0.00295	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000157	0.00295	CbGpPWpGaD
Riluzole—Asthenia—Methotrexate—bone cancer	0.000154	0.000414	CcSEcCtD
Riluzole—ABCG2—Metabolism—NDUFA12—bone cancer	0.000154	0.0029	CbGpPWpGaD
Riluzole—Feeling abnormal—Doxorubicin—bone cancer	0.000154	0.000412	CcSEcCtD
Riluzole—Gastrointestinal pain—Doxorubicin—bone cancer	0.000152	0.000409	CcSEcCtD
Riluzole—Pruritus—Methotrexate—bone cancer	0.000152	0.000408	CcSEcCtD
Riluzole—CYP1A1—Biological oxidations—GSTP1—bone cancer	0.000149	0.0028	CbGpPWpGaD
Riluzole—Hypersensitivity—Epirubicin—bone cancer	0.000148	0.000398	CcSEcCtD
Riluzole—Urticaria—Doxorubicin—bone cancer	0.000148	0.000397	CcSEcCtD
Riluzole—Abdominal pain—Doxorubicin—bone cancer	0.000147	0.000395	CcSEcCtD
Riluzole—Body temperature increased—Doxorubicin—bone cancer	0.000147	0.000395	CcSEcCtD
Riluzole—Diarrhoea—Methotrexate—bone cancer	0.000147	0.000395	CcSEcCtD
Riluzole—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	0.000147	0.00276	CbGpPWpGaD
Riluzole—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000146	0.00276	CbGpPWpGaD
Riluzole—Asthenia—Epirubicin—bone cancer	0.000144	0.000388	CcSEcCtD
Riluzole—Pruritus—Epirubicin—bone cancer	0.000142	0.000382	CcSEcCtD
Riluzole—Dizziness—Methotrexate—bone cancer	0.000142	0.000382	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000141	0.00266	CbGpPWpGaD
Riluzole—Diarrhoea—Epirubicin—bone cancer	0.000138	0.00037	CcSEcCtD
Riluzole—Hypersensitivity—Doxorubicin—bone cancer	0.000137	0.000368	CcSEcCtD
Riluzole—Vomiting—Methotrexate—bone cancer	0.000137	0.000367	CcSEcCtD
Riluzole—Rash—Methotrexate—bone cancer	0.000136	0.000364	CcSEcCtD
Riluzole—Dermatitis—Methotrexate—bone cancer	0.000136	0.000364	CcSEcCtD
Riluzole—Headache—Methotrexate—bone cancer	0.000135	0.000362	CcSEcCtD
Riluzole—Asthenia—Doxorubicin—bone cancer	0.000134	0.000359	CcSEcCtD
Riluzole—Dizziness—Epirubicin—bone cancer	0.000133	0.000357	CcSEcCtD
Riluzole—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000132	0.00249	CbGpPWpGaD
Riluzole—Pruritus—Doxorubicin—bone cancer	0.000132	0.000354	CcSEcCtD
Riluzole—SCN5A—Axon guidance—MMP2—bone cancer	0.000131	0.00247	CbGpPWpGaD
Riluzole—Vomiting—Epirubicin—bone cancer	0.000128	0.000344	CcSEcCtD
Riluzole—Nausea—Methotrexate—bone cancer	0.000128	0.000343	CcSEcCtD
Riluzole—ABCG2—Metabolism—NT5C3A—bone cancer	0.000128	0.0024	CbGpPWpGaD
Riluzole—Diarrhoea—Doxorubicin—bone cancer	0.000127	0.000342	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000127	0.0024	CbGpPWpGaD
Riluzole—Rash—Epirubicin—bone cancer	0.000127	0.000341	CcSEcCtD
Riluzole—Dermatitis—Epirubicin—bone cancer	0.000127	0.00034	CcSEcCtD
Riluzole—Headache—Epirubicin—bone cancer	0.000126	0.000338	CcSEcCtD
Riluzole—Dizziness—Doxorubicin—bone cancer	0.000123	0.000331	CcSEcCtD
Riluzole—Nausea—Epirubicin—bone cancer	0.00012	0.000321	CcSEcCtD
Riluzole—Vomiting—Doxorubicin—bone cancer	0.000118	0.000318	CcSEcCtD
Riluzole—Rash—Doxorubicin—bone cancer	0.000117	0.000315	CcSEcCtD
Riluzole—Dermatitis—Doxorubicin—bone cancer	0.000117	0.000315	CcSEcCtD
Riluzole—Headache—Doxorubicin—bone cancer	0.000117	0.000313	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—MET—bone cancer	0.000112	0.00211	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—CDK4—bone cancer	0.000112	0.00211	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000111	0.00209	CbGpPWpGaD
Riluzole—Nausea—Doxorubicin—bone cancer	0.000111	0.000297	CcSEcCtD
Riluzole—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.000109	0.00206	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—NDUFA12—bone cancer	0.000104	0.00196	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.0001	0.00188	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.0001	0.00188	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—MMP9—bone cancer	9.85e-05	0.00185	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—GSTP1—bone cancer	9.49e-05	0.00179	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	9.36e-05	0.00176	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—MMP2—bone cancer	9.35e-05	0.00176	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—NT5C3A—bone cancer	8.64e-05	0.00163	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—EGFR—bone cancer	7.96e-05	0.0015	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—TP53—bone cancer	7.9e-05	0.00149	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—MMP9—bone cancer	7.03e-05	0.00132	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—NDUFA12—bone cancer	6.65e-05	0.00125	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—EGFR—bone cancer	5.68e-05	0.00107	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—ENO2—bone cancer	5.59e-05	0.00105	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—NT5C3A—bone cancer	5.51e-05	0.00104	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—DHFR—bone cancer	5.19e-05	0.000976	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GNA11—bone cancer	4.85e-05	0.000912	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CYP3A4—bone cancer	4.4e-05	0.000827	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—ENO2—bone cancer	3.79e-05	0.000712	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GSTP1—bone cancer	3.76e-05	0.000708	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—DHFR—bone cancer	3.51e-05	0.000661	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GNA11—bone cancer	3.28e-05	0.000618	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CYP3A4—bone cancer	2.98e-05	0.00056	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.96e-05	0.000557	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GSTP1—bone cancer	2.55e-05	0.000479	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—ENO2—bone cancer	2.41e-05	0.000454	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—DHFR—bone cancer	2.24e-05	0.000421	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GNA11—bone cancer	2.09e-05	0.000394	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PTGS2—bone cancer	1.95e-05	0.000367	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CYP3A4—bone cancer	1.9e-05	0.000357	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.89e-05	0.000355	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GSTP1—bone cancer	1.62e-05	0.000305	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PTGS2—bone cancer	1.32e-05	0.000248	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PTGS2—bone cancer	8.41e-06	0.000158	CbGpPWpGaD
